Clinical trial
Impact Des Neurotomies Périphériques du Membre supérieur Chez l'Enfant Atteint de Paralysie Cérébrale
NCT07915466 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Impact Des Neurotomies Périphériques du Membre supérieur Chez l'Enfant Atteint de Paralysie Cérébrale
- Lead sponsor
- Hospices Civils de Lyon
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- November 15, 2026
- Completion date
- June 15, 2027
- Enrollment
- 21 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
cerebral palsy infantile, upper limb spasticity
Arms
As registered; 1 arm.
-
Children with cerebral palsy who have undergone a peripheral neurotomy of the upper limb.
Children with cerebral palsy who have undergone a peripheral neurotomy of the upper limb (musculocutaneous and/or median and/or ulnar), assessed preoperatively and 12-15 months after surgery, using a standardised battery of tests performed as part of routine clinical practice.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Melbourne Test - Version 2 (MA2).
To mesure the impact of a peripheral neurotomy of the upper limb (musculocutaneous and/or median and/or ulnar) in children with CP on range of motion and dexterity.
The range of motion and dexterity scores from the MA2 are used as the main criteria. The MA2 assesses the quality of unilateral upper limb function during standardized tasks (approach, grasping, release, manipulation). It is intended for children aged 2.5 to 15 years with neurological impairment.
The assessment is filmed according to a standardized protocol and scored retrospectively from the video. Four scores expressed as percentages are obtained: range of motion, precision, dexterity, and fluidity of movement. The tool has excellent reliability, both intra- (R = 0.97) and inter-examiner (R = 0.95).
Lead sponsor's other trials
Hospices Civils de Lyon, most recent start first.
+1,861 more trials See the organization page
Similar trials
Same condition (Cerebral Palsy) and phase, most recent start first.
+460 more trials See the condition page